Teladoc price target raised to $70 from $50 at KeyBanc. KeyBanc analyst Donald Hooker raised his price target for Teladoc to $70 from $50 looking into 2H18 and following the acquisition of Advance Medical. The analyst reiterates an Overweight rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.